Zura Bio Limited Class A (ZURA)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$4.15−$0.0100 (−0.24%) on the dayAs of the close; data may be delayed.
ZURA price, last 12 months
Key stats
- Previous close
- $4.16
- Open
- $4.29
- Day range
- $3.92 – $4.37
- 52-week range
- $2.07 – $7.44
- Volume
- 1.3M
- Avg volume (20 days)
- 1.6M
- Market cap
- $387.1M
Performance
1W−7.0%
1M−30.7%
3M−22.4%
6M−31.3%
YTD−20.8%
1Y+81.2%
vs S&P 500, 1Y+64.4 pts
Technicals and fundamentals
About Zura Bio Limited Class A
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $387.1M